Pcv9 Non-Persistent Use of Antihypertensive Drugs Leads to Increased Risk of Hospitalizations for Acute Myocardial Infarction or Stroke

Breekveldt-Postma, NS; Siiskonen, SJ; Beest, FJ Penning-van; Falvey, Heather; Vincze, G; Erkens, JA; Herings, R.M.C.

doi:10.1016/s1098-3015(10)63626-1

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In another study investigating the relationship between persistence (defined as < 60 days gap between refills) with antihypertensive therapy and the risk of MI/stroke, multivariate analysis showed that persistent users were at significantly lower risk of MI/stroke than non‐persistent patients (relative risk 0.88, 95% confidence interval: 0.82–0.94) (31). Better compliance with antihypertensive therapy has also been shown to reduce the risk of hospitalisation (32), while better compliance with antidiabetic medication has been shown to reduce emergency room visits by 26% over a 2‐ to 3‐year period (33).…”

Section: Discussionmentioning

confidence: 99%

The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review

Cramer

Benedict

Muszbek

et al. 2007

International Journal of Clinical Practice

427

324

View full text Add to dashboard Cite

Summary Objectives: To review studies of patient compliance/persistence with cardiovascular or antidiabetic medication published since the year 2000; to compare the methods used to measure compliance/persistence across studies; to compare reported compliance/persistence rates across therapeutic classes and to assess whether compliance/persistence correlates with clinical outcomes. Methods: English language papers published between January 2000 and November 2005 investigating patient compliance/persistence with cardiovascular or antidiabetic medication were identified through searches of the MEDLINE and EMBASE databases. Definitions and measurements of compliance/persistence were compared across therapeutic areas using contingency tables. Results: Of the 139 studies analysed, 32% focused on hypertension, 27% on diabetes and 13% on dyslipidaemia. The remainder covered coronary heart disease and cardiovascular disease (CVD) in general. The most frequently reported measure of compliance was the 12‐month medication possession ratio (MPR). The overall mean MPR was 72%, and the MPR did not differ significantly between treatment classes (range: 67–76%). The average proportion of patients with an MPR of > 80% was 59% overall, 64% for antihypertensives, 58% for oral antidiabetics, 51% for lipid‐lowering agents and 69% in studies of multiple treatments, again with no significant difference between treatment classes. The average 12‐month persistence rate was 63% and was similar across therapeutic classes. Good compliance had a positive effect on outcome in 73% of the studies examining clinical outcomes. Conclusions: Non‐compliance with cardiovascular and antidiabetic medication is a significant problem, with around 30% of days ‘on therapy’ not covered by medication and only 59% of patients taking medication for more than 80% of their days ‘on therapy’ in a year. Good compliance has a positive effect on clinical outcome, suggesting that the management of CVD may be improved by improving patient compliance.

show abstract

Section: Discussionmentioning

confidence: 99%

The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review

Cramer

Benedict

Muszbek

et al. 2007

International Journal of Clinical Practice

427

324

View full text Add to dashboard Cite

show abstract

Public health value of fixed‐dose combinations in hypertension

et al. 2008

View full text Add to dashboard Cite

ARB I olmesartan interruption in cardiovascular and cardiorenal continuum: antihypertensive and nephroprotective effects (part 1)

Bubnova

Геннадьевна²

2014

CardioSomatics

View full text Add to dashboard Cite

The article provides an overview of the efficacy and tolerability of one of the representatives of the class angiotensin receptor blockers II - olmesartan medoxomil (Kardosal). Analyzed are the characteristics and pharmacological activity of olmesartan medoxomil antihypertensive monotherapy, in combination with other antihypertensive drugs, in different groups of patients. The article describes the renal protective properties of the drug, its safety profile. It also discusses the reasons for poor adherence therapy in patients with arterial hypertension.

show abstract

Pcv9 Non-Persistent Use of Antihypertensive Drugs Leads to Increased Risk of Hospitalizations for Acute Myocardial Infarction or Stroke

Cited by 3 publications

References 0 publications

The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review

The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review

Public health value of fixed‐dose combinations in hypertension

ARB I olmesartan interruption in cardiovascular and cardiorenal continuum: antihypertensive and nephroprotective effects (part 1)

Contact Info

Product

Resources

About